$1.510
0.000 (0.00%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
RNAZ Prediction & Forecast by Similar Chart Analysis
Alphio's RNAZ stock price prediction model matches the current Transcode Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.51 (+0.10%). The 1-week path is $1.53 (+1.16%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Transcode Therapeutics Inc Stock?
Transcode Therapeutics Inc (RNAZ) is not a good buy right now due to its extremely low RSI of 25.149, indicating oversold conditions, and a staggering year-to-date change of -79.59%. The stock is currently trading at $1.51, significantly below its 52-week high of $12.60, which suggests a lack of investor confidence and potential for further declines. The main risk is its negative earnings trend, with a net income loss of -$19,510,296 in Q1 2026, which raises concerns about its financial viability.
RNAZ stock price ended at $1.51 on Friday, after rising 0.00%
Transcode Therapeutics Inc (RNAZ) last closed at $1.51, gaining +0.00%. These facts feed the 1-day and 1-week RNAZ price prediction above.
Forecast Drivers
Transcode Therapeutics Inc (RNAZ) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
Similar Chart Patterns
Stocks whose recent price path most closely matches RNAZ, ranked by similarity.
Seasonality analysis for RNAZ
Historically the probability of a positive November return for RNAZ is 0.00%. February offers the highest probability of a positive month at 60.34%, while June is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
10-year price projections for RNAZ
| Month | Min Price | Avg Price | Max Price | Potential ROI |
|---|---|---|---|---|
| Nov 2026 | $11.60 | $11.70 | $13.54 | +674.54% |
| Dec 2026 | $10.48 | $12.00 | $12.58 | +694.87% |
In 2026, Transcode Therapeutics Inc (RNAZ) is projected to range from $10.48 to $13.54.
Transcode Therapeutics Inc 2026 monthly forecast
In Nov 2026, Transcode Therapeutics Inc is projected to average $11.70, with a low of $11.60 and high of $13.54.
In Dec 2026, Transcode Therapeutics Inc is projected to average $12.00, with a low of $10.48 and high of $12.58.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.